Comparing two assays for clinical genomic profiling: the devil is in the data.
- Published in:
- 2015
- By:
- Publication type:
- Letter to the Editor
Works matching AU Stephens, Phil J.
Results: 8
1
2
A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.
- Published in:
- PLoS Computational Biology, 2018, v. 14, n. 2, p. 1, doi. 10.1371/journal.pcbi.1005965
- By:
- Publication type:
- Article
3
Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
- Published in:
- Oncologist, 2019, v. 24, n. 6, p. 791, doi. 10.1634/theoncologist.2018-0334
- By:
- Publication type:
- Article
4
Hybrid Capture‐Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1‐Mutant Cholangiocarcinoma Harboring a Novel YWHAZ‐BRAF Fusion.
- Published in:
- Oncologist, 2018, v. 23, n. 9, p. 998, doi. 10.1634/theoncologist.2017-0645
- By:
- Publication type:
- Article
5
Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden.
- Published in:
- Lung Cancer: Targets & Therapy, 2018, v. 9, p. 45, doi. 10.2147/LCTT.S161738
- By:
- Publication type:
- Article
6
A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib.
- Published in:
- Case Reports in Oncology, 2014, v. 7, n. 3, p. 628, doi. 10.1159/000367780
- By:
- Publication type:
- Article
7
Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib.
- Published in:
- Case Reports in Oncology, 2014, v. 7, n. 2, p. 343, doi. 10.1159/000363377
- By:
- Publication type:
- Article
8
Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary.
- Published in:
- Case Reports in Oncology, 2014, v. 7, n. 2, p. 503, doi. 10.1159/000365326
- By:
- Publication type:
- Article